checkAd

    Sophiris - Der Zug kommt ins Rollen - - 500 Beiträge pro Seite

    eröffnet am 01.08.16 13:11:56 von
    neuester Beitrag 24.03.17 14:18:30 von
    Beiträge: 40
    ID: 1.236.085
    Aufrufe heute: 0
    Gesamt: 11.964
    Aktive User: 0

    ISIN: CA83578Q2099 · WKN: A1W39X
    0,0300
     
    EUR
    -85,15 %
    -0,1720 EUR
    Letzter Kurs 20.05.20 Tradegate

    Werte aus der Branche Pharmaindustrie

    WertpapierKursPerf. %
    0,7500+50,00
    3,8000+38,18
    3,6600+33,58
    1,2500+22,55
    0,6393+21,19
    WertpapierKursPerf. %
    31,00-13,60
    3,8500-16,12
    16,675-17,65
    1,4600-27,00
    3,6400-38,62

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 01.08.16 13:11:56
      Beitrag Nr. 1 ()
      Sophiris (SPHS) entwickelt derzeit ein Medikament zur Behandlung von Prostatakrebs im Frühstadium. Dabei wird den Probanden lediglich eine einmalige Injektion verabreicht.
      Die Phase 2a wurde Anfang Juni erfolgreich abgeschlossen. Von 18 Probanden verschwand der Tumor bei zwei Probanden komplett, bei 7 ging er zurück. Hervorzuheben ist hierbei, das die Probanden unterschiedlich hohe Dosen verabreicht bekamen und bei der richtigen Dosierung die Erfolgsaussichten wesentlich höher sein dürften.
      Aufgrund des Milliardenmarktes und der Einfachheit der Verabreichung ist Sophiris für mich ein Vervielfachungskandidat. Die MK liegt derzeit bei etwa 100 Mio USD.
      Avatar
      schrieb am 01.08.16 13:13:42
      Beitrag Nr. 2 ()
      Hier die entsprechende PM:

      June 9, 2016
      Sophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer
      Topsalysin successfully ablated tumor cells in patients with clinically significant localized disease
      Investor webcast scheduled for today at 2:00 p.m. Pacific Time
      SAN DIEGO and VANCOUVER, British Columbia, June 9, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the biopsy results from all 18 patients enrolled in the Phase 2a proof of concept study of topsalysin in localized prostate cancer. The one-time administration of topsalysin was well tolerated with no serious adverse events and no new safety signals being reported. Topsalysin demonstrated an ability to ablate tumor cells in 50 percent of patients (9/18 patients) six months after treatment in a patient population with pre-identified, clinically significant prostate cancer. The results support advancing topsalysin into a Phase 2 study to confirm dose and optimize delivery.

      "These promising early results open up the possibility of treating early prostate cancer by the simple administration of an injection into the prostate - something that could be done in an office setting," according to Dr. Mark Emberton, Investigator, Dean, Faculty of Medical Sciences, University College London and Honorary Consultant Urologist at University College London Hospital NHS Foundation Trust.

      All 18 patients enrolled completed the study. Biopsy data at six months following treatment showed that:

      Two men experienced complete ablation of their targeted tumor with no evidence of any tumor remaining at 6 months;
      Seven men experienced a partial response, defined as either a reduction in the maximum cancer core length or a reduction in Gleason pattern;
      Nine patients had no response to treatment.
      "It was impressive to observe complete tumor ablations in this proof of concept study. We have demonstrated that topsalysin can safely ablate prostate tumor cells, so these responses increase our confidence that topsalysin could obviate or prolong the time to the need for radical therapy in this patient population," stated Dr. Hashim Ahmed, Principal Investigator for the study, Division of Surgery and Interventional Sciences, University College London. "With the experience from this study, we believe we can further improve responses by optimizing dosing topsalysin based on the size of the tumor and not the prostate and optimizing the delivery of topsalysin, which we will confirm in a larger Phase 2 study."

      Allison Hulme, Ph.D., chief operating officer and head of research and development at Sophiris, added: "The breakthrough for us is the ability to inject topsalysin, an enzymatically-activated ablative agent, directly into the identified tumor using imaging technology. Topsalysin has been engineered to be activated only by enzymatically-active PSA, which is only found in the prostate tissue. We believe that with the favorable side effect profile observed to date, topsalysin has the potential to become a focal targeted therapy for the ablation of localized prostate cancer while avoiding many of the complications and side effects associated with radical treatments that are aimed at the entire prostate."

      The Phase 2a proof of concept study was a single-center, open-label study at University College London, which is well known for the focal treatment of prostate cancer in the UK. In this study, previously obtained multiparametric magnetic resonance images (mpMRIs) of each patient's prostate tumor lesions are mapped to real-time three-dimensional transrectal ultrasound using an elastic image-fusion software. These images are used to guide the injection of topsalysin to treat a single, histologically-proven, clinically significant prostate cancer lesion. The primary objective of the study was to evaluate the safety and tolerability, and the key efficacy variable was the change in the treated lesion on targeted biopsy after 6 months. The study was designed to assess whether topsalysin has the potential to provide patients with clinically significant, localized, low to intermediate risk prostate cancer a tissue-sparing cancer treatment that carries little in the way of side effects. A total of 18 patients were enrolled and treated in this study. Detailed results from this study will be presented at a future medical conference.

      Webcast scheduled for today at 2:00 p.m. Pacific Time

      The Sophiris management team will host a conference call and webcast today, June 9, at 2:00 p.m. Pacific Time to review the topsalysin prostate cancer data. Dr. Hashim Ahmed, University College London and Principal Investigator of the prostate cancer study will also participate in the call.

      A live audio webcast will be accessible on the "Investor Relations" page of the Sophiris corporate website at www.SophirisBio.com. A replay will be available at the same location.

      About Localized Prostate Cancer

      Prostate cancer is the second most common form of cancer in men in the US with an estimated 220,800 new cases in 2015. Approximately 80 percent of patients in the US are diagnosed with localized disease. Research has shown that patients with early, localized disease have a low likelihood of the cancer spreading beyond the confines of the prostate; however, many men with clinically significant localized disease choose to undergo radical treatment. Radical therapies include surgery to remove the entire prostate and/or radiation. Potential toxicities from radical treatments can be significant and permanent and include erectile dysfunction, urinary incontinence, and rectal toxicity.

      Topsalysin for the Targeted Treatment of Localized Prostate Cancer

      Topsalysin (PRX302) has the potential to provide a focal targeted therapy for the ablation of localized prostate cancer while potentially avoiding many of the complications and side effects associated with whole gland radical treatments. The increasing use of multiparametric magnetic resonance imaging (mpMRI) and advances in mapping previously obtained mpMRI images with real-time three-dimensional ultrasound images enables physicians to more accurately locate tumors within the prostate when taking biopsies. This increases the accuracy with which men with clinically significant lesions are identified. It also enables the injection of an ablative agent, such as topsalysin, directly into previously identified clinically significant tumors located within the prostate.

      Topsalysin, an inactivated pore-forming protein, was engineered to be activated only by enzymatically-active PSA, which is present only in prostate tissue. The targeted focal treatment of prostate cancer is in line with current treatments for solid tumors such as breast and liver, where the goal is to remove the tumor and preserve as much of the organ as possible.

      About Sophiris

      Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin has also successfully completed a Phase 2a study for the treatment of clinically significant, localized low to intermediate risk prostate cancer prior to radical therapy. For more information, please visit www.sophiris.com.

      Certain statements included in this press release may be considered forward-looking, including expectations about the potential use of topsalysin for the ablation or focal treatment of prostate cancer tumors, expectations that the Company will able to use data from the proof of concept study to develop more effective delivery and dosing protocols for future clinical trials and implications that the Company will be able to continue to advance the development of topsalysin. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Some of the risks and uncertainties that could cause actual results, performance or achievements to differ include without limitation, risk associated with clinical trial development, including the risks that clinical data from a subset of patients may not be predicative of clinical data observed in subsequent patients or in subsequent clinical trials of the same drug candidate and other risks associated with the process of developing, manufacturing commercial scale drug products, obtaining regulatory approval of and commercializing treatments that are safe and effective, and risks relating to obtaining sufficient capital to enable the Company to continue to operate as a going concern and continue to advance clinical development of topsalysin. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, clinical trial results, market acceptance, ability to raise capital and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



      To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sophiris-bio-reports…

      SOURCE Sophiris Bio Inc.

      News Provided by Acquire Media

      http://investor.sophirisbio.com/releasedetail.cfm?ReleaseID=…
      Avatar
      schrieb am 01.08.16 13:16:13
      Beitrag Nr. 3 ()
      Hier ein ganz guter und aktueller Artikel über Sophiris:

      Sophiris Bio, Inc. Potential Buyout Valuation Prediction
      Hello all traders and investors,

      I hope everyone is enjoying the weekend so far! I wanted to share this post and get feedback on your estimates for a valuation on SPHS upon a potential buyout.

      Please note before reading: This post contains personal opinion and speculation. This post also contains estimated sales figures, relies on the assumption that Topsalsyin gets FDA approval in the future (risk involved), and is based among other forward looking statements and speculation. Please read this post in its entirety.

      To start off, let's take a look at some recent real-world biotech valuations (both buyout and partnership valuations) that have already unfolded.

      The following article from Business Insider was shared on StockTwits by a user named @modigliani10, whom I first saw the link posted by.
      http://www.businessinsider.com/jounce-inks-25-billion-collab…
      This link provides details of Celgene's recent partnership with biotech startup Jounce. Jounce has only been around for a few years and is working on a immunotherapy drug to combat cancer cells using the body's immune system. Their treatment has not even finished a phase 1 clinical trial yet. Recently, Celgene entered into a deal giving Jounce up to 2.5 billion dollars to develop and commercialize its pipeline. Now, that does not mean that Jounce is worth 2.5 billion dollars, but it is a nice comparison for Sophiris (whose treatment is much further along the clinical trial path than Jounce) in negotiations nonetheless.

      The next link I would like to bring into consideration for valuation comparison is the following:
      http://fortune.com/2016/04/28/abbvie-stemcentx/
      This article by Fortune features a deal between AbbVie Inc. and Stemcentrx (a private company focused on the treatment of various forms of cancer through stem cells). This deal could end up being worth as much as 10.2 billion dollars! The deal is as follows: AbbVie agrees to buy Stemcentrx for a guaranteed 5.8 billion upfront in cash and stock, 4 billion in contingent milestones, and the remaining money comes from on hand asset balances that the private company holds currently included in the deal. Here's where it gets interesting for Sophiris investors. Stemcentrx has 5 drug candidates, but their lead candidate which treats a potential 10-15% of the lung cancer population, just finished its phase 1 trials. It is very early stage with very good, but not great results. If you read my earlier posts on Sophiris, you will know that their drug is further along in trials with great results (tumor ablations, partial ablations, no serious side effects that we know of, easy treatment, etc). For an early stage company to get a 10.2 billion dollar price tag in this market is a pretty exciting comparison to keep in the back of our minds.

      The third link I would like to share is from the Wall Street Journal:
      http://www.wsj.com/articles/merck-to-acquire-biotech-company…
      Merck recently bought Afferent for $1.25B ($500M upfront and $750M upon milestone completions). Afferent is a biotech company whose drug just completed a successful phase 2b trial for.. get this.. chronic cough, primarily. Yes, a drug that reduces the frequency of coughing attracted a valuation of about 1 billion dollars. What does that say for Sophiris' valuation? I'll let you decide this one.

      The final link I would like to share does not relate to valuation, per se, but it does help Sophiris' case competition-wise.
      https://www.bostonglobe.com/business/2016/07/26/tokai-pharma…
      This mature company ended its prostate cancer drug program and related clinical trials. Another prostate cancer drug, unfortunately for the lives of many individuals affected by this disease, failed to reach high enough expectations to continue on in its program. Sophiris' drug candidate has proven its worth in earlier stages to the point that future trials are certain and the outlook is bright for its program. The fact that another company had to end its development of its prostate cancer drug should only help increase the buyout valuation of Sophiris from a competition standpoint.

      Now, let's look at the real reasons why I believe SPHS will attract a pretty penny on its own. We know that Sophiris is led by great management with decades of biotech experience including 2 buyouts in the past as CEO. We all know that SPHS' drug Topsalysin has two applications, BPH and prostate cancer. We also know that these combined markets are estimated at a total market dollar value of over 50 billion by the end of this decade - huge. The treatment size of these markets is closer to 15 billion, however. The great thing about this drug candidate is that it is injected into the prostate/tumor in an office setting. It gets better. This drug has no serious adverse side effects, a patient can continue with regular life as soon as leaving the office, and the office visit for treatment is no longer than a routine doctor's visit check-up! Simply amazing. More and more men will unfortunately be diagnosed with BPH (enlarged prostate) and prostate cancer as the years go on. This company's target market will continue to grow rapidly in the years ahead. Big pharma knows all of this, they want a drug like this in their pipeline, and they will either spend many years and hundreds of millions of dollars TRYING to develop something as good as Tops. or buy Sophiris instead. It's that simple in my eyes.

      With all of this and previous posts in mind, let's get down to the numbers.

      Assumptions:
      -BPH treatment market value in 2014 was: $2 billion - upon hypothetical approval of drug in let's say 2 years: $2.5 billion
      (2014 figure obtained from: https://healthcare.globaldata.com/media-center/press-release…

      -Prostate Cancer (PC) treatment market value in 2014: $7.6 billion, in 2021: $13.6 billion, upon hypothetical approval of drug in 2 years: $11 billion
      (source for 2014 and 2021 figures: http://gbiresearch.com/media-center/press-releases/global-pr…

      -Corporate tax rate on total annual sales=25%

      -Discount rate (per year) to calculate net present value (present value of future cash flows)=15% (above average for US corporation valuations in order to reach a conservative estimate)

      -Topsalysin is able to obtain a market share of 10% in BPH and PC markets the first two years after FDA approval, followed by 25% market share in years 3-5 (very conservative estimates, especially the first two years)

      -50% reduction in net present value of future cash flows due to uncertainty in timeline for FDA approval, future trial success rates, FDA rejection possibility, and capital needed by the acquirer to fund the final rounds of clinical trials

      Excel spreadsheet calculation for current valuation of Sophiris Bio, Inc. based on estimated future sales of Topsalysin as an FDA approved drug to treat BPH and Prostate Cancer (complete speculation) - used Excel NPV formula to calculate NPV and other Excel calculations above:













      Let's not forget that I used $2.5B and $11B for the overall BPH and PC markets, respectively, each of the 5 years of estimated future cash flows. In reality, this market will likely grow substantially each of those 5 years, again further downplaying the potential sales that Topsalysin is likely to generate upon FDA approval. Also, I cut the NPV of 5 years worth of projected future AFTER TAX cash flows from the drug by 50%! That is a huge risk factor being applied to the already conservative figures used.

      NOW, do I think that SPHS will receive a $3B valuation? ABSOLUTELY NOT.
      Readers, please understand that I know this company will not sell for 3 billion dollars, especially when the current market cap is approximately 125 million. No large corporation will pay a 24x premium! I did this to show the POTENTIAL future cash flows of this valuable drug. These are estimated figures, and my OPINION, not real sales figures. I do think that the current valuation of the company is extremely low, and therefore believe we will see a continued run-up towards the next press release.

      After spending time calculating the possible value of Topsalysin, and therefore Sophiris as a whole, I would be shocked if Randall Woods sold his company for less than $750 million. This figure represents 1/4 of the net present value of estimated projected future cash flows from Topsalysin and a fair valuation at this stage in my opinion. My only worry in regards to this BO target is the current stock price. I know big pharma will not want to pay a 2,400% premium, yet alone a 600% premium for a company! This will make them look bad to their shareholders, and their Board of Directors is highly unlikely to go for it. SPHS needs to continue to move higher next week, in my opinion, in order to get a fair valuation during BO negotiations. The coming weeks should get very interesting leading up to the next PR by SPHS. I truly hope that Mr. Woods is able to attract a fair buyout valuation for his company. I believe Sophiris is currently worth at least $750 million.

      Thank you for stopping by THFH Blog. Best of luck to all of the investors and traders!

      Please feel free to add your email to the subscription list (using the "Subscribe for New Post Alerts by Email" at the top right banner of your screen), so that you receive real time updates on new blog posts! More articles on a range of financial, political, and entertainment topics will be posted in the future.

      Disclaimer: This is not investment or trading advice, just my personal opinion. Please seek professional advice before investing or trading with real money.

      Posted by TheHedgeFundHouse at 9:34 AM No comments:
      Email This
      BlogThis!
      Share to Twitter
      Share to Facebook
      Share to Pinterest

      Friday, July 29, 2016
      SPHS: Trade or Invest?
      Hello Fellow Hedgies,

      After spending weeks reading thousands of posts on StockTwits regarding Sophiris Bio, Inc, it is clear to me that some people are torn between being a trader and being an investor. Personally, I tend to invest more than trade. I find that it reduces frequency of entry and exit mistakes, as well as fits my personal trading goals better. However, I do not see anything wrong with either side. It's just a matter of preference. In this short post, I will break down why I chose to invest in, a.k.a. buy and hold, SPHS instead of trade SPHS.

      1. Recent Volatility - SPHS has seen daily trading volumes over the past couple of weeks ranging from about 2 million shares all the way up to 28 million shares. For a company with total OS at under 21 million shares currently, THAT IS A LOT OF VOLUME! With so many shares trading hands, and such violent moves up and down on the charts, I do not feel confident enough in day trading a stock like this. Yes, volatility is a day trader's M.O., but with news just around the corner, I'm not confident that day trading this ticker is the way to be playing this. That leads to my 2nd point...

      2. Time Sensitive Expectation of News - With volatility and volume so high, I cannot see the point in trying time your entry and exit perfectly multiple times throughout the week when news could literally come out any minute! With news possibilities ranging from (in my opinion) a partnership with a couple hundred million dollars in upfront cash, in order to fund trials leading to a FDA new drug application, all the way up to a potentially $1,000,000,000+ buy out, the timing logic of day trading SPHS does not make sense to me.

      3. Silence - Piggybacking off of my last numbered reason, the lack of press releases, no conference scheduling, or lack of any other communication from the company since the stellar phase 2a POC prostate cancer tumor ablation results/conference call is interesting. Why would a company go through all of this trouble, release ABOVE EXPECTATION results, sound very upbeat about the results in a conference call shortly after release, then nothing.. silence.. I think I may know. I believe it's because that they are currently in negotiations with big pharma. Generally, there is a "gag order" placed on all parties involved (company being bought out: a complete gag order and companies doing the bidding: more of a nondisclosure agreement/semi-gag order on related business operations). That's my reasoning, and I could absolutely be wrong! Last time I checked, news helped day traders make money, so with NO news releases I would again recommend investing in this, not trading. The next news could be a monster press release.

      4. Fundamentals - I discussed the fundamental reasons why I am bullish on SPHS in the last THFH Blog post. Why is this important in deciding whether to invest in or trade a stock? I believe that a solid fundamental outlook of a company always favors a buy and hold strategy. With all of the positive fundamentals aligning at such a key point in the company's life, I believe it is acceptable to "sit on" this investment for the foreseeable future without wavering stance in the 'could I be making more profits somewhere else right now' debate.

      5. Finally, I acknowledge the emotional side of trading. When it comes to investing for me, a catch phrase usually can describe a lot of the emotion. This phrase is FOMO, or "Fear Of Missing Out." I am guilty of FOMO, as many traders often are. Why would I sell SPHS now when there is the possibility of news of a partnership or buy out next week? I'm not taking that chance!


      A new Sophiris Bio, Inc. Potential Buyout Valuation post will be available for viewing tomorrow. Stay tuned.

      Please feel free to add your email to the subscription list (using the "Subscribe for New Post Alerts by Email" box to the right of your screen), so that you receive real time updates on new blog posts! More articles on a wider range of financial, political, and entertainment topics will be posted in the future.

      Thank you again for stopping by. Best of luck to all of the investors and traders!

      Disclaimer: This is not investment or trading advice, just my personal opinion. Please seek professional advice before investing or trading with real money.
      Posted by TheHedgeFundHouse at 8:52 AM No comments:


      https://thehedgefundhouse.blogspot.de/
      Avatar
      schrieb am 01.08.16 13:26:18
      Beitrag Nr. 4 ()
      Die Website:

      http://www.sophirisbio.com/

      Derzeit gibt es 16,15 Mio Aktien.
      Haupthandelsplatz ist die Nasdaq: SPHS

      1 Antwort
      Avatar
      schrieb am 01.08.16 13:27:46
      Beitrag Nr. 5 ()
      Antwort auf Beitrag Nr.: 52.961.530 von strongbuyamitelo am 01.08.16 13:26:18Vielleicht ist jemand so nett und stellt nen RT Chart hier rein. Bei mir funktioniert es leider nicht.

      Trading Spotlight

      Anzeige
      Rallye II. – Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…mehr zur Aktie »
      Avatar
      schrieb am 04.08.16 13:11:45
      Beitrag Nr. 6 ()
      2 Antworten
      Avatar
      schrieb am 19.08.16 15:21:46
      Beitrag Nr. 7 ()
      Antwort auf Beitrag Nr.: 52.988.962 von strongbuyamitelo am 04.08.16 13:11:45Erinnert mich alles ein wenig an Santhara, die von unter 2 Euro auf über 120 Euro gestiegen ist. Das war aber mal.

      Hier geht es um Sophiris Bio ein Nasdaq Wert. Diese Aktie kommt von weit unten und hat nach einigen Korrekturen einen beachtlichen Weg nach oben bestritten.

      Erstaunlich das Ganze. Wo geht aber die Reise hin?

      Hier mal die Nachricht zur Phase II a

      Translator Deutsch:

      https://translate.google.de/translate?hl=de&sl=en&u=http://w…

      Englisch:

      http://www.nasdaq.com/press-release/sophiris-bio-reports-suc…

      https://translate.google.de/translate?hl=de&sl=en&u=http://w…

      In Deutschland kaufen lohnt nicht. Spread zu hoch. Daher, bei Interesse direkt in USA ordern.

      Stuttgart:

      https://www.boerse-stuttgart.de/de/boersenportal/wertpapiere…

      Der Kurs kommt von ganz unten. Korrekturen gehören dazu. Doch es steckt eine Menge Kraft im Anstieg. kaufkraft. Aktuell 2 Mio Aktien short. Was aber hier nichts wilrdes ist.



      Halte die 10,00 Dollar durchaus für möglich.






      Angaben von WO übernommen !

      Details zu Sophiris Bio
      Unternehmen

      Sophiris Bio Inc
      Branche

      Biotechnologie
      Herkunft

      Kanada
      Website

      www.protoxtherapeutics.com
      Aktienanzahl

      16,15 Mio.
      Marktkapitalisierung


      76,84 Mio€
      Indizes

      Nasdaq Comp
      Symbole

      WKN: A1W39X
      SYMBOL: BFF1
      VALOR: 22137595



      http://ae.advfn.com/p.php?pid=staticchart&s=N^SPHS&t=23&p=5&…


      Hier liegt m.E. eine menge Potenzial im Kurs.

      Viel Glück und Erfolg!
      1 Antwort
      Avatar
      schrieb am 21.08.16 11:54:24
      Beitrag Nr. 8 ()
      Watchlist
      Habe den Wert seit zwei Wochen auf meiner WL. Die Ergebnisse aus Phase 2 sind nicht nur ermutigend, sondern sensationell. Für viele war es bisher unvorstellbar, durch eine einmalige Infusion einen Tumor verschwinden zu lassen.

      Allein diese Nachricht hat die Szene aufhorchen lassen. Der Börsenwert der Firma ist bereits 2-3 mal durch verschiedene Hände gegangen und lässt vermuten, dass hier gerne grössere Investoren einsteigen würden.

      Meine Vermutung ist eine in Kürze anstehende KE um die Anzahl der handelbaren Aktien zu erhöhen. Hierbei werden sich grosse Fonds bzw. Banken beteiligen und spätestens am JE mit dem coversge beginnen. Ohne weitere Erkenntnisse bzw. Ergebnisse aus weiteren Testphasen halte ich eine MK von 500 Mio. Für mehr als gerechtfertigt.

      Den nächsten downmove werde ich für eine Positionierung nutzen mit KZ 20 $.

      Für mich ist die Firma zur Zeit das mit Abstand heisseste Eisen der Branche.
      Avatar
      schrieb am 22.08.16 14:30:26
      Beitrag Nr. 9 ()
      Ich bin nach wie vor sehr überrascht, dass der Wert hier im Forum kaum Beachtung findet, wo doch die angegebenen Fakten mehr als positiv sind. Auch in den USA hält man sich noch sehr bedeckt.
      Momentan vorbörslich wieder bei über 6USD.
      Ärgere mich, dass ich bei 4 USD vorletzte Woche nicht nachgelegt habe.
      Gruß @ all
      Avatar
      schrieb am 22.08.16 14:43:29
      Beitrag Nr. 10 ()
      Antwort auf Beitrag Nr.: 53.095.731 von sobio am 19.08.16 15:21:46

      Danke für den Chart :)
      Avatar
      schrieb am 22.08.16 22:15:11
      Beitrag Nr. 11 ()
      Kapitalerhöhung
      Sophiris Bio kündigt öffentliche Angebot von Stammaktien und Optionsscheine Vorgeschlagen
      Drucken
      SOPHIRIS BIO INC (NASDAQ: SPHS).
      Intraday Aktien - Chart
      Heute: Montag, 22. August 2016

      Klicken Sie hier für mehr SOPHIRIS BIO INC. Charts.
      SAN DIEGO und VANCOUVER, British Columbia , August 22, 2016 / PRNewswire / - Sophiris Bio Inc. (NASDAQ: SPHS) ( "Sophiris"), ein biopharmazeutisches Unternehmen , PRX302 (topsalysin) für die Behandlung von urologischen Erkrankungen zu entwickeln, gab heute bekannt , dass es anzubieten und zu verkaufen beabsichtigt, vorbehaltlich Markt- und anderen Bedingungen, die Stammaktien und Optionsscheine zusätzliche Stammaktien an einem garantierten öffentlichen Angebot zu erwerben. Es kann keine Zusicherung gegeben werden, ob , wenn das Angebot abgeschlossen sein kann, oder als auf die tatsächliche Größe oder Bedingungen des Angebots.

      Piper Jaffray & Co. agiert als alleiniger Book-Running Manager für das Angebot.

      Die Wertpapiere oben beschrieben werden von Sophiris nach einer wirksamen Shelf Registration Statement , eingereicht von Sophiris bei der Securities and Exchange Commission ( "SEC") angeboten , die auf Kraft getretene 3 Oktober 2014 . Ein vorläufiger Prospektnachtrag zu dem Angebot im Zusammenhang werden eingereicht werden bei der SEC und wird auf der Website der SEC unter http://www.sec.gov gelegen zur Verfügung. Exemplare des vorläufigen Prospektnachtrag und der begleitenden Prospekts für dieses Angebot im Zusammenhang, wenn verfügbar, sind erhältlich bei Piper Jaffray & Co., per Post an Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, telefonisch unter (800) 747-3924 oder per E - Mail an prospectus@pjc.com.

      Diese Pressemitteilung stellt weder ein Angebot zum Verkauf oder eine Aufforderung zur Abgabe eines Angebots, diese Wertpapiere zu kaufen, noch soll ein Verkauf dieser Wertpapiere in irgendeinem Staat oder irgendeiner anderen Jurisdiktion dort sein, in dem ein solches Angebot, eine solche Aufforderung oder Verkauf vor der rechtswidrig wäre Registrierung oder Qualifizierung gemäß den Wertpapiergesetzen eines solchen Staates oder einer anderen Jurisdiktion.

      Über Sophiris

      Sophiris Bio Inc. ist ein biopharmazeutisches Unternehmen in der Entwicklung topsalysin, eine klinische Phase, zielgerichtete Therapie für die Behandlung von urologischen Erkrankungen. Topsalysin hat erfolgreich eine klinische Phase-3-Studie für die Behandlung der Symptome von gutartiger Prostata Hyperplasie (BPH) abgeschlossen und ist als wirksam als Arzneimittel zu sein, weniger invasiv als die chirurgischen Eingriffe und ohne die sexuelle Nebenwirkungen, die mit den bestehenden Therapien gesehen . Topsalysin hat auch eine Phase-2a-Studie für die Behandlung von klinisch signifikanten abgeschlossen, lokalisiert niedrigem bis mittlerem Risiko von Prostatakrebs vor der radikalen Therapie. Für weitere Informationen, besuchen Sie bitte www.sophirisbio.com.

      Safe Harbor / Zukunftsgerichtete Aussagen

      Die Aussagen in dieser Pressemitteilung, die nicht streng historischer Natur sind, einschließlich Aussagen im Zusammenhang mit dem vorgeschlagenen Angebot von Wertpapieren durch Sophiris, sind zukunftsgerichtete Aussagen. Diese Aussagen sind nur Prognosen basieren auf aktuellen Informationen und Erwartungen und beinhalten eine Reihe von Risiken und Unsicherheiten beinhalten. Tatsächliche Ereignisse oder Ergebnisse können daher wesentlich von den Erwartungen in jeder dieser Aussagen aufgrund verschiedener Faktoren, einschließlich Marktrisiken und Unsicherheiten und der Erfüllung der üblichen Abschlussbedingungen für ein Angebot von Wertpapieren unterscheiden. Für eine Diskussion dieser und anderer Faktoren finden Sie in Sophiris Jahresbericht auf Formular 10-K für das Jahr zum 31. Dezember 2015 sowie Sophiris 'nachfolgenden Einreichungen bei der SEC. Sie sind daher nicht unangemessen auf diese zukunftsgerichteten Aussagen zu setzen, die hiervon ab dem Zeitpunkt nur sprechen. Diese Vorsicht ist unter den sicheren Hafen-Bestimmungen des Private Securities Litigation Reform Act von 1995. Alle zukunftsgerichteten Aussagen werden durch diese vorbehaltlichen Aussagen in ihrer Gesamtheit qualifiziert und Sophiris nimmt keine Verpflichtung, diese Pressemitteilung zu revidieren oder zu aktualisieren, um Ereignisse oder Umstände zu reflektieren, nach dem Datum hiervon, sofern dies nicht gesetzlich vorgeschrieben ist.

      Unternehmen Kontakt:
      Peter Slover
      Chief Financial Officer
      (858) 777-1760
      Unternehmenskommunikation und Investor Relations:

      Jason Funken

      Canale Kommunikation

      Corporate Communications und IR

      (619) 849-6005

      jason@canalecomm.com

      Michael Moore

      NATIONAL Equicom

      Anlegerbeziehungen

      (858) 886-7813

      mmoore@national.ca


      Um die ursprüngliche Version auf PR Newswire zu sehen, visit:http://www.prnewswire.com/news-releases/sophiris-bio-announc…

      SOURCE Sophiris Bio Inc.


      Copyright 2016 PR Newswire



      Das ging ja dann doch schneller als ich es erwartet habe. Werde mir morgen eine erste Position um die 5$ aufbauen. After hours -13% bei 5,05. Ein Schelm wer Böses dabei denkt....
      1 Antwort
      Avatar
      schrieb am 23.08.16 11:28:57
      Beitrag Nr. 12 ()
      Antwort auf Beitrag Nr.: 53.114.208 von Stockfinder am 22.08.16 22:15:11Ging bis 4 USD runter. Vollkommen überzogen.
      Avatar
      schrieb am 23.08.16 11:33:20
      Beitrag Nr. 13 ()
      Werde heute demnach an der Nasdaq eine erste Position aufbaue. Meine Vermutung zur Vorgehensweise hat sich im ersten Schritt als richtig erwiesen.
      1 Antwort
      Avatar
      schrieb am 23.08.16 11:56:45
      Beitrag Nr. 14 ()
      Antwort auf Beitrag Nr.: 53.116.869 von Stockfinder am 23.08.16 11:33:20Nun ja, ist ja nicht schwer. KE kommt immer, wenn ein Unternehmen sich in der Anfangsphase befindet.:)
      Avatar
      schrieb am 23.08.16 12:19:58
      Beitrag Nr. 15 ()
      Hier mal eine Seite mit RT/ Aktionärsstruktur...
      http://www.nasdaq.com/de/symbol/sphs/real-time
      Avatar
      schrieb am 23.08.16 21:55:52
      Beitrag Nr. 16 ()
      Einstieg zu 3,89$. Eine neue Aktie kostet 4 $ incl. Option, Ausübung wären ebenfalls 4$. Somit hat sophiris ausreichend cash in der Kasse, um den Blockbuster-Kandidaten topsalysin in Eigenregie weiter zu entwickeln....
      1 Antwort
      Avatar
      schrieb am 24.08.16 11:34:35
      Beitrag Nr. 17 ()
      Antwort auf Beitrag Nr.: 53.122.236 von Stockfinder am 23.08.16 21:55:52Hier die entsprechende PM:

      http://ih.advfn.com/p.php?pid=nmona&article=72274562
      Avatar
      schrieb am 24.08.16 17:50:34
      Beitrag Nr. 18 ()
      Position zu 3,47$ vervollständigt. In ein paar Tagen/WOCHE werden die Fakten/Ergebnisse wieder im Vordergrund stehen...Geduld ist angesagt, verfolge hier keine kurzfristigen Interessen!
      Avatar
      schrieb am 30.08.16 00:13:03
      Beitrag Nr. 19 ()
      Sophiris Bio Closes Underwritten Public Offering
      Print
      SOPHIRIS BIO INC. (NASDAQ:SPHS)
      Historical Stock Chart
      1 Month : From Jul 2016 to Aug 2016

      Click Here for more SOPHIRIS BIO INC. Charts.
      SAN DIEGO and VANCOUVER, British Columbia, Aug. 26 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that it has closed its previously announced underwritten public offering. The terms of the completed offering are consistent with the terms which were outlined in the Company's press release on August 23, 2016.

      Piper Jaffray & Co. is acted as sole book-running manager for the offering. Maxim Group LLC is acted as co-manager for the offering.

      With the proceeds from the offering, the Company plans to conduct a second Phase 2 clinical trial of topsalysin for the treatment of localized prostate cancer. Consistent with its recently completed proof of concept trial, this new trial will utilize previously obtained MRI images of a patient's prostate mapped to real time 3D ultrasound to target the delivery of topsalysin directly into and around a pre-identified clinically significant tumor. The primary objectives of the trial will be safety and tolerability of topsalysin when used to focally treat a targeted clinically significant tumor with potential efficacy assessed by targeted biopsy of the treated area, six months after treatment. The Company expects that this clinical trial will enroll approximately 40 patients at two or more trial sites and the Company is exploring potential trial sites in the United States. The Company expects to have six month biopsy data from the trial in the second half of 2017.

      The Company will also use the proceeds from the offering for working capital and general corporate purposes, which may include research and development expenses, general and administrative expenses, manufacturing expenses and the payment of monthly principal and interest payments to Oxford Financial LLC. The Company believes that its cash, cash equivalents and short-term investments, together with the net proceeds from the offering, will fund its operations into at least the second quarter of 2018.

      The offering was made by the Company pursuant to an effective shelf registration statement filed by the Company with the Securities and Exchange Commission ("SEC") that became effective on October 3, 2014. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Piper Jaffray & Co., by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

      This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

      About Sophiris

      Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 3 clinical trial for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin has also successfully completed a Phase 2a clinical trial for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophirisbio.com.

      Safe Harbor / Forward-Looking Statements

      Statements in this press release that are not strictly historical in nature, including statements related to the use of proceeds from the offering and the Company's planned second Phase 2 clinical trial, including the size, trial sites and timing of such clinical trial, are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including risks and uncertainties related to being a clinical-stage biopharmaceutical company, which may require changes to the planned use of proceeds, and to the commencement and conduct of clinical trials. For a discussion of these and other factors, please refer to the Company's annual report on Form 10‑K for the year ended December 31, 2015 as well as the Company's subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

      http://ih.advfn.com/p.php?pid=nmona&article=72301031

      Zusammengefasst wird die Versuchsreihe mit 40 Probanden unter professionelleren Bedingungen fortgeführt und Ergebnisse in der zweiten Hälfte 2017 erwartet. Geld ist durch die Erlöse vorhanden.

      Gruß @ all
      Avatar
      schrieb am 02.09.16 16:13:02
      Beitrag Nr. 20 ()
      So, zu durchschnittlich 3.04 USD heute wieder rein. Denke allzu weit wird es nicht mehr runtergehen. Da ist zwar ein Gap bei 85ct. Das wird wohl aber nie geschlossen werden.
      Frei nach Kostolany werde ich mit diesem Paket nun ein Jahr schlafen und dann mal schauen, was daraus geworden ist. :)

      Gruß in das noch bescheidene Forum
      Avatar
      schrieb am 08.09.16 10:44:32
      Beitrag Nr. 21 ()
      was läuft denn hier schief ?
      2 Antworten
      Avatar
      schrieb am 08.09.16 11:03:26
      Beitrag Nr. 22 ()
      Antwort auf Beitrag Nr.: 53.233.257 von hector14 am 08.09.16 10:44:32
      Zitat von hector14: was läuft denn hier schief ?


      Denke die haben nach der Dilution was Sie wollten nämlich wieder ordentlich Cash ;)
      Der Kurs wurde hochgezogen um eine möglichst gute / satte Kapitalerhöhung zu erzielen.

      Jetzt musste Geduld haben, der Kurs kann jedoch Biotech like schnell wieder drehen.
      1 Antwort
      Avatar
      schrieb am 13.09.16 08:36:15
      Beitrag Nr. 23 ()
      Antwort auf Beitrag Nr.: 53.233.521 von Aurum2010 am 08.09.16 11:03:26Eine kleine Posi ist nun im Depot. Allen investierten viel Erfolg.
      Avatar
      schrieb am 15.09.16 19:04:35
      Beitrag Nr. 24 ()
      Heute kam wieder eine Empfehlung mit Kursziel 8USD heraus:

      https://www.thestreet.com/story/13741531/1/sophiris-bio-sphs…

      Gruß @ all
      2 Antworten
      Avatar
      schrieb am 15.09.16 19:05:19
      Beitrag Nr. 25 ()
      Antwort auf Beitrag Nr.: 53.283.672 von strongbuyamitelo am 15.09.16 19:04:35Sorry, jetzt mit der Verlinkung:

      https://www.thestreet.com/story/13741531/1/sophiris-bio-sphs…
      1 Antwort
      Avatar
      schrieb am 20.09.16 06:47:07
      Beitrag Nr. 26 ()
      Antwort auf Beitrag Nr.: 53.283.675 von strongbuyamitelo am 15.09.16 19:05:19Also 8 USD halte ich doch für das Erste etwas zu hoch angesetzt :D
      Avatar
      schrieb am 27.09.16 16:17:03
      Beitrag Nr. 27 ()
      Die letzten zwei Tage kommt etwas Bewegung rein.
      Avatar
      schrieb am 29.09.16 21:02:47
      Beitrag Nr. 28 ()
      In der letzten PM ist ja zu lesen, dass Ergebnisse der Studie in der zweiten Hälfte 2017 erwartet werden. Kann also sein, dass jetzt wirklich hier erstmal nichts mehr kommt, außer Quartals-, Halbjahreszahlen.:rolleyes::rolleyes:
      Immerhin reichen die Mittel bis zur 2 Hälfte 2018, also erstmal keine weitere Dilution.
      Ich hoffe mal, dass zumindest Zwischenberichte veröffentlicht werden.
      Avatar
      schrieb am 30.09.16 11:48:24
      Beitrag Nr. 29 ()
      Short Interest in Sophiris Bio Inc. (SPHS) Expands By 35.9%
      September 30th, 2016 • 0 comments • Filed Under • by ABMN Staff

      Sophiris Bio logoSophiris Bio Inc. (NASDAQ:SPHS) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 1,929,722 shares, a growth of 35.9% from the August 31st total of 1,419,895 shares. Approximately 11.2% of the shares of the company are sold short. Based on an average daily volume of 1,930,398 shares, the short-interest ratio is currently 1.0 days.

      An institutional investor recently raised its position in Sophiris Bio stock. Citadel Advisors LLC boosted its stake in shares of Sophiris Bio Inc. (NASDAQ:SPHS) by 65.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,176 shares of the biopharmaceutical company’s stock after buying an additional 19,402 shares during the period. Citadel Advisors LLC owned about 0.23% of Sophiris Bio worth $106,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.29% of the company’s stock.

      Shares of Sophiris Bio (NASDAQ:SPHS) opened at 3.08 on Friday. The stock’s market capitalization is $69.66 million. The company has a 50 day moving average price of $3.54 and a 200-day moving average price of $2.48. Sophiris Bio has a 52-week low of $0.67 and a 52-week high of $8.55.



      Several brokerages have recently commented on SPHS. Roth Capital began coverage on Sophiris Bio in a research report on Thursday, September 15th. They issued a “buy” rating and a $8.00 price objective on the stock. Echelon Wealth Partners restated a “buy” rating and issued a $5.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th. Maxim Group restated a “buy” rating and issued a $4.00 price objective on shares of Sophiris Bio in a research report on Friday, June 10th. Finally, Piper Jaffray Cos. began coverage on Sophiris Bio in a research report on Tuesday, August 30th. They issued an “overweight” rating and a $7.00 price objective on the stock.

      Sophiris Bio Company Profile

      Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

      http://www.americanbankingnews.com/2016/09/30/short-interest…

      Könnte interessant werden...
      Avatar
      schrieb am 30.09.16 11:50:01
      Beitrag Nr. 30 ()
      W:O könnte übrigens die Anzahl der Aktien mal aktualisieren. Momentan sind es etwa 23 Mio shares, nicht mehr 16 Mio...
      1 Antwort
      Avatar
      schrieb am 30.09.16 11:52:54
      Beitrag Nr. 31 ()
      Antwort auf Beitrag Nr.: 53.382.474 von strongbuyamitelo am 30.09.16 11:50:01Aktuelle Zahl vom 2.8.2016:
      22,62 Mio. outstanding.

      https://ycharts.com/companies/SPHS/shares_outstanding
      Avatar
      schrieb am 11.10.16 14:15:58
      Beitrag Nr. 32 ()
      October 10, 2016
      Sophiris Bio to Present at the 2016 BIO Investor Forum
      SAN DIEGO and VANCOUVER, British Columbia, Oct. 10, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the 2016 BIO Investor Forum. The presentation is scheduled for Tuesday, October 18, 2016 at 10:30 a.m. PDT in San Francisco.

      The presentation will be webcast live and can be accessed through the Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's website for 90 days.

      About Sophiris
      Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. Topsalysin has also successfully completed a Phase 2a clinical trial for the treatment of localized low to intermediate risk prostate cancer. For more information, please visit www.sophiris.com.

      Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

      Company Contact:
      Peter Slover
      Chief Financial Officer
      (858) 777-1760


      Corporate Communications and Investor Relations:
      Michael Moore
      NATIONAL Equicom
      Investor Relations
      (858) 886-7813
      mmoore@national.ca
      Jason Spark
      Canale Communications
      Corporate Communications and IR
      (619) 849-6005
      jason@canalecomm.com


      http://investor.sophirisbio.com/releases.cfm


      Irgendetwas neues wird es wohl zu der aktuellen Studie an Infos geben. Denke, dass zeitgleich nächsten Dienstag ne PM rausgehauen wird...
      Avatar
      schrieb am 11.10.16 14:18:56
      Beitrag Nr. 33 ()
      Hier nochmal ne aktuelle Übersicht und Möglichkeiten.


      Sophiris Bio: How Far Off Is Topsalysin's FDA Application?
      Oct.10.16 | About: Sophiris Bio (SPHS)

      The company has enough cash, cash equivalents and short-term investments to fund its operations into at least the second quarter of 2018.

      With the introduction of option chain, there is leverage to hold long positions.

      The company already has a license agreement with Japan for commercialization of Topsalysin.

      BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.

      The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.



      Source: The San Diego Union-Tribune

      Introduction:

      Company

      Sophiris Bio Inc. (NASDAQ:SPHS) is developing Topsalysin, a targeted therapy for the treatment of urological diseases. The company has completed eight clinical trials for Topsalysin development. The company plans to conduct a second Phase 2 clinical trial of Topsalysin for the treatment of localized prostate cancer. It expects that this clinical trial will enroll approximately 40 patients and expects to have six months of biopsy data from the trial in the second half of 2017.



      Sources: FDA and Sophiris Bio; notations added by author.

      Drug Development/Clinical Research

      BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.


      http://seekingalpha.com/article/4011293-sophiris-bio-far-top…
      Avatar
      schrieb am 17.10.16 18:54:53
      Beitrag Nr. 34 ()
      Morgen um 16.30 Uhr beginnt die Präsentation. Sicherlich daher das heutige höhere Handelsvolumen und die bisher 10% up. Bin mal gespannt, ob es nen Zwischenstand gibt...

      Gruß @ all
      Avatar
      schrieb am 10.11.16 19:16:21
      Beitrag Nr. 35 ()
      Die Quartalszahlen sind da:

      http://investor.sophirisbio.com/releases.cfm

      Gruß @ all
      Avatar
      schrieb am 11.11.16 12:02:50
      Beitrag Nr. 36 ()
      Zacks: Sophiris Bio Inc. (SPHS) Given Consensus Rating of “Strong Buy” by Brokerages
      Posted by Joseph Griffin on Nov 11th, 2016 // No Comments

      Sophiris Bio logoSophiris Bio Inc. (NASDAQ:SPHS) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
      Brokerages have set a 1-year consensus price objective of $6.75 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also given Sophiris Bio an industry rank of 84 out of 265 based on the ratings given to related companies.
      Several equities analysts have commented on SPHS shares. Maxim Group upped their price objective on shares of Sophiris Bio from $4.00 to $6.00 and gave the company a “buy” rating in a report on Wednesday, August 10th. Piper Jaffray Cos. began coverage on shares of Sophiris Bio in a report on Tuesday, August 30th. They issued an “overweight” rating and a $7.00 price objective on the stock. Finally, Roth Capital began coverage on shares of Sophiris Bio in a research report on Thursday, September 15th. They issued a “buy” rating and a $8.00 target price for the company.


      Large investors have recently made changes to their positions in the stock. KCG Holdings Inc. boosted its stake in shares of Sophiris Bio by 152.3% in the third quarter. KCG Holdings Inc. now owns 42,920 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 25,907 shares during the last quarter. Airain ltd boosted its stake in Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 31,713 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Sophiris Bio during the third quarter valued at $139,000. Citadel Advisors LLC boosted its stake in Sophiris Bio by 65.2% in the second quarter. Citadel Advisors LLC now owns 49,176 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 19,402 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Sophiris Bio by 90.3% in the second quarter. Vanguard Group Inc. now owns 331,000 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 157,100 shares in the last quarter. 5.38% of the stock is owned by institutional investors.
      Shares of Sophiris Bio (NASDAQ:SPHS) opened at 2.87 on Tuesday. Sophiris Bio has a 52-week low of $0.80 and a 52-week high of $8.55. The firm has a 50-day moving average of $2.88 and a 200 day moving average of $2.76. The firm’s market cap is $64.91 million.
      About Sophiris Bio
      Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

      https://www.tickerreport.com/banking-finance/2261663/zacks-s…

      Es tut sich so einiges bei sophiris. Im dritten Quartal haben mehrere Investoren ihre Bestände aufgestockt. Sehr gutes Zeichen.:)

      Gruß @ all
      Avatar
      schrieb am 18.01.17 21:16:33
      Beitrag Nr. 37 ()
      was geht ?
      Avatar
      schrieb am 24.03.17 14:14:26
      Beitrag Nr. 38 ()
      2 Antworten
      Avatar
      schrieb am 24.03.17 14:16:39
      Beitrag Nr. 39 ()
      Antwort auf Beitrag Nr.: 54.605.898 von strongbuyamitelo am 24.03.17 14:14:26Ups,
      da war ich etwas voreilig: Die Daten der 2a Studie werden am 26.3. präsentiert.:yawn:
      Avatar
      schrieb am 24.03.17 14:18:30
      Beitrag Nr. 40 ()
      Antwort auf Beitrag Nr.: 54.605.898 von strongbuyamitelo am 24.03.17 14:14:26Ich bin gerade ein bisschen blöd:
      Die Ergebnisse der ERFOLGREICHEN Phase 2a werden am 26.3. veröffentlicht. Sorry, für die Verwirrung.


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.

      Investoren beobachten auch:

      WertpapierPerf. %
      +0,47
      0,00
      +2,61
      +1,97
      +2,42
      -3,68
      +2,48
      +0,30
      +0,96
      +0,10
      Sophiris - Der Zug kommt ins Rollen -